Biotechnology Company Receives Clearance For Alzheimer's Treatment Development

NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapeutics, has announced a significant milestone. The company's cryopreserved autologous enhanced SNK01 NK cell therapy has received clearance from its Safety Review Committee to progress into Phase 2 clinical development for treating Alzheimer's disease. $NKGEN BIOTECH(NKGN.US)$